Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed with or without Sorafenib in Advanced NSCLC
NCT00454194Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2007
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-Free Survival at 5 years. Started Sep 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00454194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454194.